Vertex to file novel CF drug on "exceptional" Phase III data
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has reported exceptionally strong Phase III results for its cystic fibrosis treatment, VX-770, in patients with a rare form of the disease – those who have a mutation in the CF gene known as G551D. They pave the way for it to file for regulatory approval in both the US and Europe in the second half of the year.